VX-103

VX-103 is an investigational **monovalent H1N1 seasonal influenza vaccine** formulated for delivery via Vaxess Technologies’ **MIMIX** dissolving microneedle array patch (MAP), which embeds inactivated split A/Guangdong-Maonan/SWL1536/2019-like (H1N1) antigen in silk fibroin microneedle tips applied intradermally to the forearm.[1][3][8] The silk-based tips dissolve in the skin to provide **sustained antigen release**, targeting dermal antigen-presenting cells and aiming to enhance and prolong humoral and cellular immune responses compared with conventional intramuscular injection.[1][3] In a first-in-human Phase 1 randomized, placebo-controlled study in healthy adults, single-dose VX-103 (7.5 µg or 15 µg HA) demonstrated acceptable local tolerability with mainly mild to moderate application-site reactions and robust hemagglutination inhibition responses fulfilling EMA/FDA serological criteria for seasonal influenza vaccines, with antibody responses durable to at least 180 days.[1][3] VX-103 is being developed by Vaxess Technologies, in collaboration with GC Biopharma, as a shelf-stable, potentially self-applied influenza vaccination modality that could improve coverage by avoiding needles, simplifying logistics, and enabling dose-sparing strategies.[4][5][7][8]

Brand names

MIMIX Patch

Other names

H1 influenza vaccine delivered by MIMIX MAPH-1 influenza vaccine delivered by MIMIX MAPH 1 influenza vaccine delivered by MIMIX MAPseasonal influenza vaccine patchMIMIX vaccine patchMIMIX microneedle patch